Dr. Jean-Yves Douillard, Professor Emeritus of Medical Oncology at the University of Nantes, France, and member of the Advisory Board of PracticeUpdate Oncology, recommends the following abstracts being presented at this year's ESMO Congress, held September 13 through 17, 2024, in Barcelona.

Friday, September 13, 2024
2:00 PM–5:30 PM CEST; Proffered Paper Session I

Non-Metastatic NSCLC

LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). G Goss

• The results of this study are much awaited. Durvalumab added after conventional chemoradiation in unresectable locally advanced NSCLC in the PACIFIC trial have been practice-changing. Post-locoregional treatment with durvalumab has demonstrated efficacy. CCTG BR.31 is questioning if this will work as well in earlier-stage, resected NSCLC.

Saturday, September 14, 2024
8:30 AM–10:00 AM CEST; Proffered Paper Session

NSCLC Metastatic

LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study. N Girard

• The combination of nivolumab with relatlimab is associated with better efficacy than nivolumab alone in stage IV melanoma. The RELATIVITY-104 study will address the question in stage IV NSCLC, comparing nivolumab plus platinum-doublet chemotherapy with or without relatlimab as a new immune checkpoint inhibitor targeting LAG-3. It will be interesting to see if immunotherapy ”intensification” will improve efficacy.

Monday, September 16, 2024
4:30 PM–6:15 PM CEST; Presidential Symposium III

Eyes to the Future

LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways. P Tomasini

• The use of immune checkpoint inhibitors is now part of the treatment of metastatic NSCLC. However, most patients will recur. The PIONeeR trial will explore potential targets associated with resistance that could offer an additional line of treatment to these patients in the context of personalized precision medicine

ESMO 2024, longkanker, aanbevolen abstracten, oncologen, medisch specialisten

---

• ESMO 2023: aanbevolen abstracten van studies bij longkanker door oncologen en medisch specialisten

---

• Regulier - Longkanker: overzicht van recente ontwikkelingen en belangrijke studies en artikelen binnen reguliere oncologie voor longkanker.